Selected passages from the FDA letter
Quoted FDA text from the published dataset. These selected excerpts are not the complete letter.
Passage 1your website offers cannabidiol (CBD) products for sale in the United States and that these products are intended to mitigate, prevent, treat, diagnose, or cure COVID-19***1*** in people.
Passage 2these products are unapproved new drugs sold in violation of section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. § 355(a).
Passage 3these products are misbranded drugs under section 502 of the FD&C Act, 21 U.S.C. § 352.
Passage 4CBD may help patients cope with symptoms and mitigate the long-term pulmonary damage of the virus.
Passage 5Some of the worst effects of COVID are caused by inflammation, and CBD is a potent anti-inflammatory.
Passage 6they found that CBD can mitigate ARDS-like symptoms . . . [a]nother study examining CBD and COVID made similar conclusions.